
The study evaluated neratinib and ado-trastuzumab-emtansine (T-DM1) for treating HER2-positive breast cancer brain metastases, both in previously treated and untreated patients. Results indicated varying efficacy between the treatments, with significant findings on overall survival and progression-free survival rates. The study highlights the complexities in managing brain metastases in HER2-positive breast cancer and suggests potential therapeutic strategies for future research.
Like
Save
Share